Publicaciones (192) Publicaciones de MARÍA DE LAS MERCEDES MARÍN ARRIAZA

2023

  1. A mutation responsible for impaired detection by the Xpert SARS-CoV-2 assay independently emerged in different lineages during the SARS-CoV-2 pandemic

    BMC Microbiology, Vol. 23, Núm. 1

  2. Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non–C. difficile diarrhea, and C. difficile–colonized patients

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Clinical impact of time to results from the microbiology laboratory in bloodstream infections caused by carbapenemase-producing Enterobacterales (TIME-CPE STUDY)

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 8, pp. 1948-1954

  4. Clinical presentation, microbiology, and prognostic factors of prosthetic valve endocarditis. Lessons learned from a large prospective registry

    PloS one, Vol. 18, Núm. 9, pp. e0290998

  5. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  6. Identification of Nocardia and non-tuberculous Mycobacterium species by MALDI-TOF MS using the VITEK MS coupled to IVD and RUO databases

    Microbial Biotechnology, Vol. 16, Núm. 4, pp. 778-783

  7. Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  8. Pneumocystis jirovecii Pneumonia Diagnostic Approach: Real-Life Experience in a Tertiary Centre

    Journal of Fungi, Vol. 9, Núm. 4

  9. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

    Critical Care, Vol. 27, Núm. 1

  10. Rapid Discrimination of Pseudomonas aeruginosa ST175 Isolates Involved in a Nosocomial Outbreak Using MALDI-TOF Mass Spectrometry and FTIR Spectroscopy Coupled with Machine Learning

    Transboundary and Emerging Diseases, Vol. 2023

  11. Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection

    Open Forum Infectious Diseases, Vol. 10, Núm. 2